|
Title
|
|
|
|
Progression-free survival and safety at 3.5 years of follow-up : results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| What is this summary about? This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug). The first results from the PRIMA study were published in 2019, when patients had participated in the PRIMA study for about 1.2 years. The article this PLSP is based on reports longer-term data from the PRIMA study, when patients had participated in the PRIMA study for about 3.5 years. Patients were monitored (or followed) for a longer time to understand how well niraparib continued to work and to evaluate whether the safety of niraparib changed with additional time being monitored. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Future oncology
| |
|
Publication
|
|
|
|
London
:
Future medicine ltd
,
2024
| |
|
ISSN
|
|
|
|
1479-6694
1744-8301
| |
|
DOI
|
|
|
|
10.2217/FON-2023-0782
| |
|
Volume/pages
|
|
|
|
20
:22
(2024)
, p. 1531-1544
| |
|
ISI
|
|
|
|
001187364100001
| |
|
Pubmed ID
|
|
|
|
38501262
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|